TY - JOUR
T1 - Personalized treatment of pain
AU - Ablin, Jacob N.
AU - Buskila, Dan
N1 - Funding Information:
Dr Ablin has served as a consultant for, received research grant support from, received payment for development of educational presentations (including service on speakers’ bureaus) from, and had travel and accommodations expenses covered and reimbursed by Pfizer. Dr Buskila reported no potential conflicts of interest relevant to this article.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Despite advances made in its understanding and treatment, chronic pain remains an unsolved and all too common problem. One of the main obstacles to successful management of pain is the high variability of many patients regarding both response to treatment and susceptibility to adverse effects, which curtails the utility of therapeutic intervention. Understanding the causes of this variability is an important challenge which may lead to a new era in rational pain management. As described in this review, however, there currently seems to be more than one possible explanation of this variability. Rational personalized pain management must take into consideration both everincreasing knowledge of pharmacogenetics and pharmacokinetics and a broad, clinically based attitude incorporating co-morbidities, both physical and psychiatric, and concomitant medications. Novel models for testing in-vivo pain processing, for example assessment of conditioned pain modulation (CPM), are also promising approaches to use of rational data for empirical treatment of pain. Last, listening to the patient and understanding the context in which pain has affected his or her life is an important part of maintaining the personal nature of therapeutic interaction with patients suffering from pain.
AB - Despite advances made in its understanding and treatment, chronic pain remains an unsolved and all too common problem. One of the main obstacles to successful management of pain is the high variability of many patients regarding both response to treatment and susceptibility to adverse effects, which curtails the utility of therapeutic intervention. Understanding the causes of this variability is an important challenge which may lead to a new era in rational pain management. As described in this review, however, there currently seems to be more than one possible explanation of this variability. Rational personalized pain management must take into consideration both everincreasing knowledge of pharmacogenetics and pharmacokinetics and a broad, clinically based attitude incorporating co-morbidities, both physical and psychiatric, and concomitant medications. Novel models for testing in-vivo pain processing, for example assessment of conditioned pain modulation (CPM), are also promising approaches to use of rational data for empirical treatment of pain. Last, listening to the patient and understanding the context in which pain has affected his or her life is an important part of maintaining the personal nature of therapeutic interaction with patients suffering from pain.
KW - Central sensitization
KW - Chronic pain
KW - Conditioned pain modulation (CPM)
KW - Fibromyalgia
KW - Genetics
KW - Narrative medicine
KW - Personalized medicine
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=84870459991&partnerID=8YFLogxK
U2 - 10.1007/s11926-012-0298-7
DO - 10.1007/s11926-012-0298-7
M3 - Article
C2 - 23292814
AN - SCOPUS:84870459991
SN - 1523-3774
VL - 15
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 1
M1 - 298
ER -